Fe-transferrin and iron loading with ferric ammonium citrate revealed no significant differences in transferrin receptor density and iron responsive protein/iron regulatory element binding activity between patients and controls. However, sensitivity to H 2 O 2 was significantly increased in patient cells, and H 2 O 2 toxicity could be completely inhibited by the ubiquitously distributing iron chelator 2,2-dipyridyl, but not by the mitochondrion-selective chelator RPA. Our data strongly suggest that frataxin deficiency does not affect the mitochondrial labile iron pool or other parameters of cellular iron metabolism and suggest a decreased antioxidative defense against extramitochondrial iron-derived radicals in patient cells. These results challenge current concepts favoring the use of mitochondrion-specific iron chelators and antioxidants to treat FRDA.
Fe-transferrin and iron loading with ferric ammonium citrate revealed no significant differences in transferrin receptor density and iron responsive protein/iron regulatory element binding activity between patients and controls. However, sensitivity to H 2 O 2 was significantly increased in patient cells, and H 2 O 2 toxicity could be completely inhibited by the ubiquitously distributing iron chelator 2,2-dipyridyl, but not by the mitochondrion-selective chelator RPA. Our data strongly suggest that frataxin deficiency does not affect the mitochondrial labile iron pool or other parameters of cellular iron metabolism and suggest a decreased antioxidative defense against extramitochondrial iron-derived radicals in patient cells. These results challenge current concepts favoring the use of mitochondrion-specific iron chelators and antioxidants to treat FRDA.
Friedreich's ataxia (FRDA) 1 is the most common inherited ataxia, affecting one in 50,000 people (1) . Clinically, Friedreich's ataxia is characterized by multiple symptoms including progressive gait and limb ataxia, dysarthria, diabetes mellitus, and hypertrophic cardiomyopathy leading to premature death (2) . There is currently no effective treatment for FRDA.
FRDA is caused by a GAA trinucleotide expansion in the frataxin gene located on chromosome locus 9q13, resulting in a reduced expression of frataxin, a small mitochondrial protein (3) (4) (5) . Because of the mitochondrial localization of frataxin, the neuro-and cardio-degenerations observed in FRDA are thought to be the result of a mitochondrial defect (1) . The importance of frataxin for viability is underscored by the recent finding that a knockout of this gene leads to early embryonic lethality in mice (6) . However, despite a large number of studies that have focused on the function of frataxin in bacteria, yeast, mice, and human cells, its role in the pathogenesis of FRDA is still largely unknown and discussed controversially (7) (8) (9) (10) . At least five hypotheses for the primary mitochondrial function of frataxin have been proposed: iron transport (7), iron/sulfur (Fe/S) cluster biosynthesis (8, 11, 12) , iron storage (1, 13) , stimulator of oxidative phosphorylation (14) , and antioxidant function (1) . In accordance with the often proposed antioxidant function of frataxin, antioxidant enzyme levels have been found to be significantly different in blood from FRDA patients compared with controls (15) , frataxin has been reported to play a critical role in repair of mitochondrial Fe/S clusters in mitochondrial aconitase (12) , and it has been shown that superoxide dismutase (SOD) genes are not induced by oxidative stress in FRDA fibroblasts, in contrast to control cells (10, 16, 17) . The prevailing hypothesis underlying the pathogenesis of FRDA, however, proposes that frataxin is somehow involved in the regulation of mitochondrial iron homeostasis and that impaired intramitochondrial iron metabolism results in iron overload and oxidative stress (10, 18, 19 ).
An accumulation of iron detected as iron deposits using Perl's staining has been consistently observed on autopsy in heart muscle of FRDA patients (20) and magnetic resonance imaging data indicate that iron also accumulates in the dentate nucleus (21) . A small but significant intramitochondrial accumulation of total iron has also been reported in one patient study (22) , while no significant increase in total mitochondrial iron under physiological cell culture conditions was found in others (1, 19, 23) . Intramitochondrial iron accumulation has been postulated to be the primary pathogenetic event initiating the production of hydroxyl radicals by Fenton chemistry, leading to inactivation of Fe/S proteins, lipid peroxidation and damage to nucleic acids and proteins, finally resulting in cell death (10, 24) . However, in a conditional knock-out mouse model for FRDA, accumulation of intramitochondrial total iron has been reported to follow a decrease in the Fe/S cluster-containing subunits of the mitochondrial electron transport chain (complexes I-III) and of the enzyme aconitase (25) , and thus was suggested to be a late event in the pathogenetic process.
The form of iron generally regarded to be responsible for the generation of highly reactive oxygen species mediating oxidative stress is termed "labile" or "chelatable iron," because of its accessibility to iron chelators (26 -28) . However, although iron is obviously involved in the pathogenesis of FRDA, the connection between frataxin deficiency and the size of the mitochondrial labile (chelatable) iron pool and its role in the pathogenesis of FRDA have not yet been characterized because of the lack of a suitable methodological approach. Therefore, using the novel mitochondrion-specific iron indicator/chelator rhodamine B-[(1,10-phenanthrolin-5-yl)aminocarbonyl]benzylester (RPA, Refs. 29 and 30), we have determined here for the first time the concentration of mitochondrial chelatable iron in FRDA cells, i.e. in FRDA patient lymphoblast and fibroblast cell lines in comparison with age-and sex-matched control cell lines. In addition, we studied the influence of decreased frataxin levels on various other parameters of iron metabolism as well as the contribution of mitochondrial chelatable iron to cell death under H 2 O 2 -induced oxidative stress in FRDA patient cells.
EXPERIMENTAL PROCEDURES
Materials-The mitochondrion-selective fluorescent iron indicator RPA was a generous gift from Prof. R. Sustmann (Institut fü r Organische Chemie, Universitä t Duisburg-Essen, Germany); RPA is available from Squarix Biotechnology GmbH (Marl, Germany). RPMI 1640 medium was from Invitrogen, Life Technologies (Karlsruhe, Germany), bovine serum albumin (BSA) from Serva (Heidelberg, Germany), and 1ϫ protease inhibitor mixture and RNaseT1 from Roche Applied Science (Basel, Switzerland). Dimethyl sulfoxide and Triton X-100 were from Merck (Darmstadt, Germany). SDS and a protein assay reagent were obtained from Bio-Rad. Fetal calf serum, ferrous ammonium sulfate, poly-L-lysine, tetramethylrhodamine methyl ester (TMRM), 2,2Ј-dipyridyl (2,2Ј-DPD), propidium iodide, basal medium Eagle (BME), chelex (chelating resin; iminodiacetic acid), hydrogen peroxide, diethylenetriaminepentaacetic acid (DTPA), apo-transferrin (Apo-Tf), ferric ammonium citrate, HEPES, dithiothreitol, and horseradish peroxidaseconjugated goat anti-mouse IgG came from Sigma. The fluorescent dye rhodamine 123 was purchased from Molecular Probes Europe BV (Leiden, Netherlands), the ECL Western blotting system from Amersham Biosciences (Freiburg, Germany), and the mouse anti-frataxin monoclonal antibody 2FRA-1G2 from Chemicon International Inc. (Temecula, CA). Radioactive iron ( 55 FeCl 3 ) and [␣-32 P]cytidinetriphosphate were obtained from PerkinElmer Life Sciences and Readysafe from Beckman. Pyridoxal isonicotinoyl hydrazone (PIH) was a generous gift from Prof. Dr. P. Ponka (Lady Davis Institute for Medical Research, Montreal, Canada). PIH (100.0 mM) was dissolved in 0.1 N NaOH, then diluted with Hanks' balanced salt solution (HBSS: 137.0 mM NaCl, 5.4 mM KCl, 1.0 mM CaCl 2 , 0.5 mM MgCl 2 , 0.4 mM KH 2 PO 4 , 0.4 mM MgSO 4 , 0.3 mM Na 2 HPO 4 , 25.0 mM HEPES, pH 7.4) and adjusted to pH 7.35 (37°C). Falcon cell culture flasks and Falcon 6-well cell culture plates were obtained from BD Biosciences, glass coverslips were from Assistent (Sondheim/Röhn, Germany), and gas mixtures from Messer Griesheim (Krefeld, Germany).
Cell Culture-Lymphoblast and skin fibroblast cell lines from Friedreich's ataxia patients and age-and sex-matched controls were established after informed consent at the Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Australia (Table I ). All studies were approved by the Royal Children's Hospital Ethics in Human Research Committee. Fibroblast cell lines were cultured on 6.2 cm 2 glass coverslips in 6-well cell culture plates or in 12.5 cm 2 culture flasks in BME supplemented with 10% fetal calf serum, L-glutamine (2.0 mM), NaHCO 3 (11.6 mM), penicillin (100 units/ml), streptomycin (100 g/ml), and HEPES (20 mM; pH 7.35, 37°C). Lymphoblast cell lines were cultured in suspension in 25 cm 2 culture flasks (kept in an upright position) in RPMI 1640 medium supplemented with 20% fetal calf serum, L-glutamine (1.6 mM), NaHCO 3 (7.5 mM), sodium pyruvate (0.8 mM), uridine (0.04 mM), penicillin (100 units/ml), streptomycin (100 g/ml), and HEPES (16 mM; pH 7.35, 37°C). All cell lines were cultured in a humidified atmosphere of 5% CO 2 , 95% air.
Determination of Mitochondrial Chelatable Iron-Mitochondrial chelatable iron of transformed lymphoblast and fibroblast cell lines from Friedreich's ataxia patients and age-and sex-matched controls was determined using the mitochondrion-selective fluorescent iron indicator RPA, the fluorescence of which is quenched by chelatable iron (26, 29 -31) .
Human fibroblasts (1.0 ϫ 10 5 cells), cultured on glass coverslips until confluency, were loaded with RPA (0.2 M) in HBSS for 20 min at 37°C, followed by an additional 15 min of incubation in dye-free buffer. Human lymphoblasts were washed once with HBSS by centrifugation (250 ϫ g for 5 min at 37°C) and attached (5 ϫ 10 6 cells/ml) to poly-Llysine-coated (5 g/cm 2 ) glass coverslips 15 min before loading the cells with RPA. Adherent lymphoblasts were incubated with RPA as described for the fibroblast cell lines. For measurements, cells were incubated in HBSS (37°C), and measurements were performed by laser scanning microscopy ( exc. ϭ 543 nm and em. Ն 560 nm (29)). After establishing the mitochondrial baseline fluorescence, the mitochondrial chelatable iron was removed from the indicator by the addition of a large excess of the membrane-permeable iron chelator PIH (2 mM) leading to a "dequenching" of the RPA fluorescence. The increase in fluorescence was taken as a measure of the concentration of the intramitochondrial chelatable iron, which was quantified using an ex situ calibration.
In other experiments, cells were incubated simultaneously with RPA and rhodamine 123 (0.2 M) in order to prove selective mitochondrial staining. In experiments with double-stained mitochondria, red fluorescence of RPA ( exc. ϭ 543 nm; em. Ն 585 nm) and green fluorescence of rhodamine 123 ( exc. ϭ 488 nm; em. ϭ 505-530 nm) were optically isolated in successive scans. At the end of the experiments, the uptake of the vital dye propidium iodide (5 g/ml) was routinely determined in order to assess loss in cell viability. The red fluorescence of propidium iodide excited at 543 nm was collected through a 560 nm long-pass filter.
Determination of 55 Fe-Tf-uptake and Functional Transferrin Receptor Density-The uptake of transferrin-bound iron by FRDA patient and control cells was studied using 55 Fe-loaded human apo-Tf. Human apo-Tf was loaded with 55 FeCl 3 according to Bates and Schlabach (32) . Fibroblasts and lymphoblasts were washed twice with their respective medium containing 50 M DTPA to remove extracellular iron and then washed once with medium alone. For the 55 Fe-Tf-uptake, the cells (5 ϫ 10 6 /ml) were incubated for 30 min in serum-free medium (37°C) supplemented with 1 mg/ml BSA, 20 mM HEPES, and 55 Fe-Tf (100 -800 nM iron). Transferrin receptor (TfR) saturation kinetics was assessed by incubating the cells with 55 Fe-Tf (0 -1600 nM iron) for 0 -45 min under the same conditions; samples were taken every 15 min. The cellular uptake of 55 Fe-Tf was terminated by separating the cells from the supernatant. Lymphoblast suspensions were centrifuged (3,000 ϫ g for 3 min at 4°C) and the pellet was purified by further centrifugation through an oil layer consisting of 80% w/w dibutylphthalate and 20% w/w dioctylphthalate. Fibroblasts were washed with serum-free medium containing 50 M DTPA to remove extracellular iron and then washed once with BME alone. Cells were lysed overnight in 500 l of 0.5 M KOH with 1% Triton X-100, and the lysates were neutralized with 250 l of 1 M HCl. Intracellular radioactivity was counted in a Packard liquid scintillation counter (Vienna, Austria) subsequent to the addition of Readysafe. Kinetic analyses were calculated with GraphPad Prism (GraphPad Software, San Diego, CA).
Assessment of H 2 O 2 Cytotoxicity-FRDA fibroblasts and control cells were cultured in 12.5 cm 2 cell culture flasks until confluency. Before starting the experiments, cells were washed twice with HBSS (37°C) and then covered with Krebs-Henseleit buffer (115 mM NaCl, 25 mM NaHCO 3 , 5.9 mM KCl, 1.2 mM NaH 2 PO 4 , 1.2 mM MgCl 2 , 2.5 mM CaCl 2 , 1.2 mM Na 2 SO 4 , 20 mM HEPES, pH 7.4), supplemented with 10 mM glucose as previously reported for murine L929 fibroblasts (33). Afterward, H 2 O 2 was added as a bolus of 500 M from a concentrated stock solution, and cells were incubated at 37°C in an atmosphere of 5% CO 2 /95% air. In some experiments, the transition metal chelators 2,2Ј-DPD (200 M) or 1,10-phenanthroline (100 M) were added to the Krebs-Henseleit buffer prior to the addition of H 2 O 2 or the cells were preincubated with deferoxamine (10 mM for 30 min in BME, followed by washing with HBSS). Other cultures were preincubated with RPA (0.2 M, in HBSS, 20 min at 37°C, followed by an additional 15 min of incubation in dye-free buffer, see above) prior to the start of the experiments. Solvent controls were included. After various periods of incubation, loss in cell viability was assessed by the release of lactate dehydrogenase (LDH) activity using a standard assay.
Western Blot Analysis-The endogenous frataxin of cultured human fibroblasts of Friedreich's ataxia patients and healthy control individuals was detected on Western blots using the mouse anti-frataxin monoclonal antibody 2FRA-1G2. Whole cell protein extracts were prepared from 75 cm 2 cell culture flasks of subconfluent cells. Cells were lysed in 200 l of extraction buffer (300 mM NaCl, 10 mM Tris, pH 7.9, 1 mM EDTA, 0.1% Nonidet P-40, 1ϫ protease inhibitor mixture) for 20 min on ice and centrifuged (3,600 ϫ g at 4°C for 5 min). The supernatant was used as whole cell extract, and the protein concentration was determined using a protein assay reagent. 100 g of protein per lane were loaded onto a 12.5% SDS-polyacrylamide gel, and after electrophoresis the gel was blotted onto nitrocellulose membranes, which were blocked with 5% nonfat milk overnight at 4°C. Incubation with the primary monoclonal antibodies against frataxin (diluted 1:2,500 in 5% BSA) was performed for 1 h at room temperature. Horseradish peroxidase-conjugated goat anti-mouse IgG was used as a secondary antibody (1:10,000 dilution, incubation for 1 h). An ECL Western blotting system was used for detection of the immunoreactive proteins according to the manufacturer's instructions.
IRP/IRE Bandshift Assay-The activity of iron regulatory proteins (IRP)/iron responsive elements (IRE) in FRDA fibroblasts and control cells was determined according to the method described by Mü llner et al. (34) . Cells were washed twice with BME containing 50 M DTPA to remove extracellular iron and then once with the medium alone. To study basal and iron-induced changes in IRP/IRE activity, cells were then incubated in the absence or presence of 150 M ferric ammonium citrate for 6 h in serum-free medium (37°C) supplemented with 1 mg/ml BSA and 20 mM HEPES. Afterward, the fibroblasts were lysed in 0.2% Nonidet P-40 buffer (40 mM KCl, 5% glycerol, 1 mM dithiothreitol, 0.2% Nonidet P-40, 10 mM HEPES, pH 7.6). Radioactive labeled IRE probes were prepared by in vitro transcription of pSPT-Fer (IRE of human ferritin H-chain mRNA (34) ) in the presence of [␣-
32 P]cytidinetriphosphate. IRE/IRP binding reactions were carried out with 2 g of protein and 640,000 cpm of 32 P-labeled IRE probe by incubation for 20 min at room temperature. Thereafter, samples were treated with 20 units of RNase T1 and 5 g/l heparin for 10 min each. RNA-protein complexes were separated in 6% non-denaturing polyacrylamide gels and fixed onto diethylaminoethyl ion exchange paper. Signals corresponding to IRP-IRE complexes were quantified by phosphorimaging (ImageQuant Software, Amersham Biosciences). The total amount of IRP1 was assessed by in vitro reduction with 3% 2-mercaptoethanol prior to the binding reaction.
Statistics-All experiments with human lymphoblasts and fibroblasts were performed in duplicate with cell lines from different patients and different age-and sex-matched controls. Cellular microfluorographs and blots shown in the figures are representative of all the corresponding experiments carried out. Other results are expressed as means Ϯ S.D. Data obtained from two groups were compared by means of Student's t test (matched values, two-tailed, paired). A p value of Ͻ 0.05 was considered significant.
RESULTS AND DISCUSSION

GAA Expansion Size and Frataxin Content of Human Fibroblasts and Lymphoblasts Derived from Friedreich's Ataxia Patients-
The size of the GAA expansions as determined by polymerase chain reaction on genomic DNA was found to range from about 600 -1300 repeats in the lymphoblast and fibroblast cultures of all patients (Table I) , thus confirming large GAA alleles on both chromosomes. To verify that the frataxin level in the FRDA patient-derived cell lines was actually decreased, Western blot analysis was carried out. Using the 2FRA-1G2 human antibody we detected a ϳ18 kDa protein, i.e. a protein with a molecular mass consistent with the one of human frataxin, in the fibroblasts of the healthy control individuals, whereas the residual frataxin levels of fibroblasts of the Friedreich's ataxia patients were barely detectable (Fig. 1 ). This result confirmed that the cells derived from Friedreich's ataxia patients and age-and sex-matched controls differed profoundly in their frataxin content, thus excluding the possibility of an artifact arising during the establishment and maintenance of the cell lines.
Mitochondrial Chelatable Iron in Cultured Human FRDA and Control Fibroblasts and Lymphoblasts-The nature of the iron that has been reported to accumulate within the mitochondria of patients with Friedreich's ataxia is yet unknown. All of the methods previously used to study changes in the intramitochondrial iron homeostasis primarily assess the total mitochondrial iron content but are not suitable to selectively determine the small fraction of mitochondrial iron that is regarded to be responsible for the initiation of iron-mediated oxidative injury, i.e. the labile (chelatable) iron (26, 27, 29, 35) . The substantial disadvantages of the disruptive methods used so far to determine/characterize the intramitochondrial iron in FRDA cells, e.g. atomic absorption spectroscopy (22) and ultrafiltration (1), result from the necessity of processing the biological material, preceding the actual measurements; the homogenization or lysis of cells or isolated mitochondria can easily lead to a mobilization of originally firmly bound (storage) iron, which is finally detected as chelatable iron (26) . To circumvent these problems, we used an approach, which allows the selective determination of the chelatable iron pool in mitochondria of viable FRDA patient cells (26, 29, 31) .
RPA strongly and selectively accumulated within the matrix space of the mitochondrial compartment of both fibroblasts and lymphoblasts (Fig. 2) as confirmed by its colocalization with the mitochondrial marker rhodamine 123 (data not shown) and was found to be non-toxic to the cells under the present exper- imental conditions. The determination of the intramitochondrial RPA concentration, by comparing the mitochondrial fluorescence after dequenching with PIH (2.0 mM) with the fluorescence of RPA standards (29) , revealed no differences between patient and control cells (data not shown). This indicates that the mitochondrial membrane potential, i.e. the driving force for the intramitochondrial accumulation of RPA (29), is not affected in human FRDA fibroblasts and lymphoblasts. This conclusion was confirmed in comparative experiments with rhodamine 123 (data not shown), a well accepted probe for the determination of the mitochondrial membrane potential (⌬⌿ M (36, 37) ). Intramitochondrial RPA concentration was sufficient in all instances to allow proper quantitative determination of mitochondrial chelatable iron; the detailed prerequisites for these measurements are outlined in Ref. 29 . When the concentration of mitochondrial chelatable iron was determined from the increase in mitochondrial RPA fluorescence (i.e. ⌬fluorescence) after addition of PIH, no significant differences in mitochondrial chelatable iron in both fibroblast and lymphoblast cultures from FRDA patients could be observed in comparison to the cells from healthy controls (Fig. 3) . Previously, a total mitochondrial iron content of about 520 ng iron/mg of mitochondrial protein had been determined in human FRDA fibroblasts and ϳ350 ng iron/mg protein in age-and sex-matched control cells (22) . Assuming a protein concentration of about 60% (v/v) in mitochondria (38) , the total mitochondrial iron concentration of human FRDA fibroblasts and control cells, i.e. of the same cell-culture model as used here, can be estimated to be as high as 5.6 mM and 3.8 mM, respectively. This suggests that mitochondrial iron chelatable by RPA constitutes only 0.03% of total mitochondrial iron of these cells (see Fig. 3 ). Conversely, this also demonstrates that the accumula- 1 and 3) and healthy control individuals (C, lanes 2 and 4) was immunoblotted with 2FRA-1G2. An ϳ18 kDa protein became apparent in the lanes of the healthy control individuals, whereas the residual frataxin of the Friedreich's ataxia patient fibroblasts was hardly detectable. An unspecific band detected by the frataxin antibody under our conditions was also used as a loading control. tion of total mitochondrial iron in cultured FRDA patient fibroblasts (about 1.8 mM, Ref. 22) is not related to an increase in the concentration of the chelatable iron pool within these organelles. Instead, an increased concentration of iron tightly bound in heme or Fe/S proteins, or possibly in a mitochondrial storage protein for iron has to be proposed, i.e. iron accessible to atomic absorption spectroscopy (22) and Perl's staining (20) , but not the RPA-detectable pool of chelatable iron, that is likely to be redox-active and therefore pathophysiologically highly important. The nature of the responsible iron-binding protein/ molecule, however, is largely unclear. It appears unlikely that an increased content of mitochondrial Fe/S-clusters in FRDA cells accounts for their higher total mitochondrial iron because Fe/S-cluster biosynthesis was found to be impaired in frataxindeficient cells (8, 11, 12 , 39) and thus should be rather decreased than increased in FRDA mitochondria. Further, we found no differences in the mitochondrial membrane potential, which depends on Fe/S-cluster proteins of the respiratory chain, between FRDA cells and controls. In addition, the pool of iron bound to Fe/S-clusters presumably is too small to explain the high difference in total mitochondrial iron as determined by Delatycki et al. (22) , and its increase appears to be no reasonable strategy to counteract the increased sensitivity toward oxidative stress (22, 23, 25) . Likewise, also mitochondrial ferritin most likely does not represent the responsible iron storage protein in human fibroblast mitochondria because its expression is restricted mainly to testis, neuronal cells, islets of Langerhans and iron-loaded mitochondria of erythroblasts of patients with sideroblastic anemia (40) . However, it cannot be ruled out that its expression is induced in frataxin-deficient cells. On the other hand, expression of human mitochondrial ferritin in frataxin-deficient yeast mutants has been found to rescue respiratory function, to prevent the development of mitochondrial iron overload and to increase cell resistance to H 2 O 2 (41) . Finally, a decreased expression of frataxin in erythroid cells has been suggested to result in mitochondrial iron sequestration for heme biosynthesis thus leading to mitochondrial iron loading in Friedreich ataxia (42) . However, the possibility that a higher heme content of FRDA fibroblasts accounts for the increase in total mitochondrial iron appears rather unlikely because heme synthesis in non-erythroid cells is known to be very low (43) . Consequently, the form in which the highly increased total mitochondrial iron in human FRDA fibroblasts is stored cannot be clarified here and may be the subject of future studies.
In contrast to studies with yeast strains that totally lack frataxin, Delatycki et al. (22) could not find a consistent pattern of sensitivity to iron exposure when comparing FRDA patient fibroblast cell lines with those of controls, a result which may be explained by the fact that in human FRDA cells frataxin is not totally absent (5). This might also explain why no significant differences in the concentration of mitochondrial chelatable iron were found between patient and control cells. The possibility that the unaltered concentration of chelatable iron in FRDA patient mitochondria resulted from iron depletion under the present culture conditions is improbable, as the cells were cultured in the presence of high serum concentrations. Similarly, it is very unlikely that RPA significantly perturbed the homeostatic equilibria in iron metabolism of the cells. Direct as well as indirect (via dynamic equilibria) mobilization of iron from heme, (putative) mitochondrial ferritin or Fe/S-clusters by RPA itself is most unlikely because the baseline fluorescence of RPA-loaded lymphoblasts and fibroblasts remained almost stable during the time course of the measurements. This suggests that the method differentiated well between the small pool of mitochondrial chelatable iron and the bulk of iron, which is bound to proteins (see above). Progressive mobilization of protein-bound iron, is also unlikely with respect to the fairly low intramitochondrial concentrations of RPA (Ͻ 10 M), the short incubation time (20 min) and the fairly large size of the RPA molecule that should impede access to a (putative) ferritin iron core. Further, almost no toxic effects became apparent when cells were loaded with RPA (0.2 M, for 20 min) and then incubated for 24 h in dye-free Krebs-Henseleit buffer. 2 Therefore, the exchange of iron ions between iron-binding or -storage proteins and RPA via dynamic equilibria appears to be too slow to significantly contribute to the mitochondrial chelatable iron pool as determined here. This is also indicated by the fact that no increase in chelatable iron was detected in FRDA fibroblasts despite their strongly increased total mitochondrial iron content (see above).
Iron uptake from 55 Fe-Transferrin-Mammals use Tf to transport ingested iron through the blood to the various tissues. At the plasma membrane, the TfR binds Tf and the complex is internalized via clathrin-coated pits (44) . In yeast, lack of frataxin has been shown to lead to an accumulation of iron in the mitochondria and hence to a secondary increase in iron import across the plasma membrane (13) . We therefore examined whether in human FRDA cells the uptake of transferrin-bound iron is increased. This determination of the uptake was carried out using concentrations where no saturation of TfR appeared. In contrast to the experiments performed with yeast, our results did not show any significant differences in the uptake of 55 Fe-Tf between the FRDA patient and control fibroblast and lymphoblast cell lines, indicating that the physiological mechanism of the transferrin-bound iron uptake across the plasma membrane is not affected in human FRDA lymphoblast and fibroblast cells (Fig. 4) .
Functional TfR Density and IRP/IRE Activity-The uptake of 55 Fe-Tf is limited by the expression and recycling of TfRs, which are located on the plasma membrane (45) . At any given time, the rate at which receptor-ligand complexes are formed is proportional to the radioligand concentration and the number of receptors still unoccupied. Binding increases with increasing 55 Fe-Tf concentrations until it plateaus when specific binding saturates the receptors.
When lymphoblast and fibroblast cell lines were incubated with 55 Fe-Tf concentrations in the range of 0 -1600 nM iron, i.e. concentrations where saturation of TfR appeared, and the amount of intracellular radioactive iron was determined every 15 min, no significant alterations in the uptake of transferrinbound iron were detectable in the FRDA patient cell lines, thus indicating cellular TfR densities comparable to the controls (Fig. 5) . This result is in line with a previous study, where the mean TfR concentrations of freshly isolated FRDA leukocytes and cultured lymphoblasts were found to be not significantly different from the control groups (46) . However, alterations in the transferrin receptor density of blood cells from FRDA patients are discussed controversially (46 -48) .
The TfR expression is controlled by the IRP/IRE system, which thereby regulates the concentration of intracellular labile (chelatable) iron. Since an iron-sulfur cluster in the IRPs responds to the availability of cytosolic labile iron, IRPs do not only regulate the concentration of labile iron but IRP activities are also regulated by this pool (43, 49 -52) . Consequently, IRP activities do reflect the concentration of the cytosolic labile iron pool and indicate the iron required by the cell for metabolic needs (53) . IREs are RNA elements that function as binding sites for IRP-1 and IRP-2 (54) . IRPs bound to multiple IREs in the 3Ј-untranslated region of the TfR1 mRNA stabilize the 2 B. Sturm, U. Bistrich, and F. Petrat, unpublished results. transcript and allow enhanced production of TfR that is crucial for cellular uptake (55) (56) (57) .
As expected from our results indicating that the TfR density is unaltered in FRDA cells, the determination of the basal IRP/IRE activity by bandshift assay (34) did not show a significant difference between FRDA cells and control cells (Fig. 6) , indicating that the concentration of the cytosolic labile iron pool was not increased in FRDA fibroblasts and lymphoblasts under basal conditions. After 6 h of iron loading with 150 M ferric ammonium citrate there was still no significant difference in IRP/IRE activity detectable between patient and control cells, strongly suggesting equal steady-state concentrations of the cytosolic labile iron pool in human FRDA cells and controls also after iron exposure.
Taken together, our studies showed no significant changes in the concentration of the mitochondrial chelatable iron pool nor in the basic parameters of iron metabolism (transferrin-mediated-iron uptake, TfR saturation/density, IRP/IRE binding activity and thus, most likely, cytosolic labile iron) in human FRDA lymphoblast and fibroblast cell lines compared with ageand sex-matched controls. These results are in line with a study by Tan et al. (58) who found changes in genes involved in Fe/S cluster synthesis but not in iron-related genes, lending no support for a direct role of frataxin in iron homeostasis. (26, 33, 59) . In line with this, several studies with fibroblasts from FRDA patients have indicated an increased sensitivity to free iron and hydrogen peroxide exposure (22, 23, 25) , leading to suggestions that an increased concentration of mitochondrial Fenton-reactive iron ions is the reason for this increased sensitivity. In the present study, however, no alterations in the mitochondrial chelatable iron pool could be observed in FRDA cells compared with control cells. Therefore, in order to verify whether the FRDA fibroblasts used in the present study are also more sensitive to H 2 O 2 , the sensitivity of the four FRDA fibroblast and control cell lines to H 2 O 2 was studied. Despite their unaltered iron homeostasis, but in line with previous studies (1, 23) , FRDA fibroblasts exhibited a significantly increased sensitivity to H 2 O 2 (500 M) compared with the ageand sex-matched control cells (Fig. 7A) .
In order to study whether this increased toxicity of H 2 O 2 was mediated by labile (chelatable) iron ions and since there is an ongoing discussion about the use of iron chelators for the treatment of FRDA, we examined the contribution of mitochondrial and of extramitochondrial chelatable iron to H 2 O 2 -induced cell Fe-transferrin of human FRDA and control fibroblasts and lymphoblasts. Fibroblasts (A) and lymphoblasts (B) from four FRDA patients and four age-and sex-matched controls were washed twice with the respective culture medium containing 50 M DTPA to remove extracellular iron and then once with medium alone. Afterward, the cells were incubated for 30 min in serumfree medium (37°C) supplemented with 1 mg/ml BSA and 20 mM HEPES in the presence of various 55 Fe-Tf concentrations (100 -800 nM iron). Finally, the cells were washed and lysed, and the amount of incorporated 55 Fe was measured using a liquid scintillation counter. Data shown are means Ϯ S.D. from four experiments performed with cell lines derived from four FRDA patients and four healthy control individuals, respectively.
FIG. 5.
Functional transferrin receptor density of human FRDA and control fibroblasts and lymphoblasts. Fibroblasts (A) and lymphoblasts (B) from an FRDA patient and an age-and sexmatched control, respectively, were washed twice with the respective medium containing 50 M DTPA to remove extracellular iron and then once with medium alone. Afterward, the cells were incubated for 0 -45 min in serum-free medium (37°C) supplemented with 1 mg/ml BSA and 20 mM HEPES in the presence of 55 Fe-Tf (0 -1600 nM iron). Samples of the cells were taken every 15 min to determine the amount of incorporated 55 Fe using a liquid scintillation counter. Data shown represent means Ϯ S.D. of two independent experiments with two cell lines. death using RPA and 2,2Ј-DPD, respectively. The fluorescent iron indicator RPA is a phenanthroline-based iron chelator that forms a redox-inactive [Fe(II) (RPA) 3 ] 2ϩ complex and exclusively complexes chelatable iron within the mitochondrial compartment (26, 29 -31) , whereas 2,2Ј-DPD predominantly chelates iron within the cytosolic and the nuclear compartment (35) . When human FRDA fibroblast cell lines were incubated with 500 M H 2 O 2 , 2,2Ј-DPD (200 M) provided almost complete protection against H 2 O 2 -induced cell death (Fig. 7B) . Other iron chelators known to complex iron within the cytosol and the nucleus (26), namely 1,10-phenanthroline (100 M) and, in line with Wong et al. (23) , deferoxamine (preincubation with 10 mM for 30 min), also rescued FRDA fibroblasts from H 2 O 2 -induced death (data not shown). In contrast, preincubation of the cells with 0.2 M RPA, leading to an intramitochondrial RPA concentration of 6.4 Ϯ 0.2 M had no significant protective effect (Fig. 7B) . A similar result was also obtained in studies with other cell types (rat liver endothelial cells and L929 fibroblasts), and confirmed at higher RPA concentrations (1-2 M) leading to higher intramitochondrial indicator concentrations, i.e. a larger excess of chelator within this compartment. When the concentration of RPA used for loading was further increased to 10 M, the indicator/chelator became detectable also within the cytosol of the cells providing protection against H 2 O 2 (data not shown).
Given that the intramitochondrial RPA concentration sufficiently (Ͼ3-fold) exceeded the concentration of mitochondrial chelatable iron due to its intramitochondrial accumulation, thus ensuring complete formation of the redox-inactive [Fe(II) (RPA) 3 ] 2ϩ complex (29, 30) , and given that RPA is a very strong chelator for Fe 2ϩ (log K(app) of 1,10-phenanthroline ϭ 21.0) (60), these data strongly suggest that mitochondrial chelatable (redoxactive) iron is not decisively involved in H 2 O 2 -induced and ironderived cell death. Our data suggest that only extramitochondrial chelatable iron (most likely within the cytosol) participates in crucial Fenton-type reactions leading to a loss in cell viability. In this context, it therefore appears unlikely that the physiological function of frataxin is to store iron in order to protect cells from mitochondrial iron-derived oxidative damage.
As iron homeostasis was not altered and mitochondrial chelatable iron also played no role in H 2 O 2 toxicity, an explanation for the increased H 2 O 2 sensitivity of FRDA patient cells could be that these cells either may experience intrinsically higher endogenous levels of oxidant stress, possibly resulting from alterations of proteins of the respiratory chain (10, 61) or do contain an oxidant-sensitive target. However, the most likely explanation is that these cells have a decreased antioxidative capacity to counteract extramitochondrial iron-derived radicals. This conclusion is important to consider in the development of iron chelators and antioxidants for the treatment of FRDA. Antioxidants like idebenone, which are supposed to act like CoQ10 to facilitate the transport of electrons in the electron transport chain, could potentially play a role in reducing the problem that is created in FRDA cells. Similarly, the clinically approved iron chelator deferiprone may have a useful role in reducing intracellular oxidative damage in FRDA patient cells, because of its ability to readily enter the cytoplasm. Our results fully back the concept that pharmacological up- FIG. 6 . IRP/IRE activity of human FRDA and control fibroblasts under low and high iron conditions. Fibroblasts from FRDA patients and age-and sex-matched controls were washed twice with BME culture medium containing 50 M DTPA to remove extracellular iron and then once with the medium alone. Then the cells were loaded with 150 M ferric ammonium citrate (FAC) for 6 h in serum-free medium (37°C) supplemented with 1 mg/ml BSA. Control samples were cultured in serum-free medium (37°C) supplemented with 1 mg/ml BSA only. Afterward, the cells were washed and lysed in 0.2% Nonidet P-40 buffer and incubated with the radioactive labeled IRE probe as described under "Experimental Procedures." Where specified, samples were additionally incubated with 3% 2-mercaptoethanol (2-ME) to obtain total IRP activity. IRP/IRE signals were quantified using the ImageQuant Software. Data shown are means Ϯ S.D. of two experiments performed with cell lines derived from three FRDA patients and three healthy control individuals, respectively. regulation of frataxin expression might provide the most effective therapy for FRDA (10) .
CONCLUSIONS
The results presented strongly indicate that in FRDA patient lymphoblast and fibroblast cells the concentration of intramitochondrial chelatable iron is not increased, despite a profound reduction in the mitochondrial frataxin content. In addition, we could not find any evidence for an alteration in cellular iron homeostasis/metabolism in these cells. Hence, our data do not support the widespread assumption that an increase in the chelatable (redox-active) iron within the mitochondria is responsible for the increased oxidative stress in FRDA cells. However, the cells showed an increased sensitivity toward H 2 O 2 toxicity, a toxicity that was found to be mediated by extramitochondrial chelatable iron. These results might suggest that frataxin deficiency associated with FRDA results in a defective antioxidative capability against extramitochondrial iron-derived radicals, a finding that would have important implications in the further development of approaches for the treatment of FRDA. Our studies further suggest that there may be significant differences in the mechanisms of mitochondrial iron homeostasis and antioxidant defense between human and yeast cells and that direct comparative studies should be very informative.
